Jan. 20, 2010 -- Two new drugs for multiple sclerosis, both taken orally, reduce the rates of relapses in multiple sclerosis patients -- sometimes keeping 80% or more of patients relapse-free during the study period -- according to new research. The new drugs, if approved, promise an end to injections for some patients.
Results of three studies looking at cladribine and fingolimod for the form of MS known as relapsing-remitting are published online in the New England Journal of Medicine. In an accompanying editorial, a doctor suggests the new drugs could provide a ''new horizon'' for patients and a welcome increase in treatment options.
"These results are big in that first of all, both these therapies look to be very effective, appear to be well tolerated, and they have a novel mechanism of action," says Jeffrey A. Cohen, MD, director of experimental therapeutics at the Mellen Center for Multiple Sclerosis at the Cleveland Clinic and lead researcher of one of the studies.
These two new options may be just the beginning, Cohen tells WebMD. "I think they are harbingers of other medicines on the horizon."
About 400,000 Americans have MS, a chronic, often disabling disease, according to the National Multiple Sclerosis Society. The body turns on itself, attacking myelin, the fatty substance protecting nerve fibers in the central nervous system, leading to damaged nerve fibers and hindering nerve impulses from traveling to and from the brain and spinal cord. That, in turn, produces symptoms such as numbness, limb weakness, and blurred vision. About 85% of MS patients are initially diagnosed with the form of MS known as relapsing-remitting, in which flare-ups are followed by remissions.
The two new drugs would be the first treatment options that don't involve injections or infusions.
Cohen's team compared fingolimod in two doses -- 1.25 milligrams or 0.5 milligrams -- with an established treatment for MS, intramuscular injection of interferon beta-1a (Avonex) at a dose of 30 micrograms per week.
When the researchers looked at the relapse rate after 12 months in 1,153 patients randomly assigned to one of the three treatment groups, they found that the relapse rate was lower in both groups getting fingolimod.